NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $32.33 +0.33 (+1.03%) (As of 08/26/2024 ET) Add Compare Share Share Today's Range$31.88▼$32.4350-Day Range$21.00▼$32.8552-Week Range$18.61▼$33.33Volume516,431 shsAverage Volume763,492 shsMarket Capitalization$2.47 billionP/E RatioN/ADividend YieldN/APrice Target$29.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Veracyte alerts: Email Address Veracyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside8.0% Downside$29.75 Price TargetShort InterestHealthy3.87% of Shares Sold ShortDividend StrengthN/ASustainability-1.02Upright™ Environmental ScoreNews Sentiment0.54Based on 4 Articles This WeekInsider TradingSelling Shares$1.22 M Sold Last QuarterProj. Earnings Growth161.54%From $0.13 to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.60 out of 5 starsMedical Sector266th out of 921 stocksMedical Laboratories Industry8th out of 18 stocks 1.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 2 research reports in the past 90 days.Read more about Veracyte's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.87% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Veracyte has recently decreased by 5.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 66.88% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.02. Previous Next 2.5 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Veracyte this week, compared to 3 articles on an average week.Search Interest12 people have searched for VCYT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,217,514.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow by 161.54% in the coming year, from $0.13 to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -34.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -34.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity[Free Event] A 3-Step Method To Generate Cash Flow From Stocks You Already OwnCharles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash flow. Simply put, this time-tested 3-step strategy allows anyone to create cash flow from the stocks you already own without selling a single share in your portfolio. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.CLICK HERE TO RSVP About Veracyte Stock (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesAugust 15, 2024 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Director Sells $658,715.40 in StockAugust 15, 2024 | insidertrades.comEvan/ Fa Jones Sells 1,032 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockAugust 26, 2024 | Unstoppable Prosperity (Ad)[Free Event] A 3-Step Method To Generate Cash Flow From Stocks You Already OwnCharles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash flow. Simply put, this time-tested 3-step strategy allows anyone to create cash flow from the stocks you already own without selling a single share in your portfolio. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.August 11, 2024 | insidertrades.comJens Holstein Sells 5,000 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockAugust 26 at 1:00 PM | stockhouse.comVeracyte Named a Greater Bay Area Top Workplace by the San Francisco ChronicleAugust 26 at 7:58 AM | msn.comHere’s Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT)August 19, 2024 | finance.yahoo.comTMDX Sep 2024 120.000 call (TMDX240920C00120000)August 19, 2024 | finance.yahoo.comTMDX Sep 2024 110.000 put (TMDX240920P00110000)August 26, 2024 | Unstoppable Prosperity (Ad)[Free Event] A 3-Step Method To Generate Cash Flow From Stocks You Already OwnCharles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash flow. Simply put, this time-tested 3-step strategy allows anyone to create cash flow from the stocks you already own without selling a single share in your portfolio. I call it "The Cash Flow Trade", and my team is going to teach you how and when to execute it in this free live event.August 18, 2024 | finance.yahoo.comISRG Aug 2024 375.000 put (ISRG240823P00375000)August 18, 2024 | finance.yahoo.comISRG Aug 2024 285.000 call (ISRG240823C00285000)August 18, 2024 | es-us.finanzas.yahoo.comGráfico interactivo de acciones de Veracyte, Inc. (VCYT) - Yahoo FinanzasAugust 16, 2024 | americanbankingnews.comEvan/ Fa Jones Sells 20,457 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockAugust 15, 2024 | investing.comVeracyte director Jones sells over $53k in company stockAugust 13, 2024 | markets.businessinsider.comAnalyst Issues Sell Rating for Veracyte Amidst Strong Q2 Growth but Limited Near-Term UpsideAugust 11, 2024 | finance.yahoo.comVeracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearAugust 9, 2024 | markets.businessinsider.comVeracyte’s Growth Momentum and Robust Test Adoption Fuel Buy RatingAugust 8, 2024 | benzinga.comVeracyte (NASDAQ:VCYT) Stock Quotes, Forecast and News SummarySee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/26/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees790Year Founded2006Price Target and Rating Average Stock Price Target$29.75 High Stock Price Target$34.00 Low Stock Price Target$26.00 Potential Upside/Downside-7.6%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E Ratio247.62 P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-13.52% Pretax Margin-13.71% Return on Equity1.52% Return on Assets1.41% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.17 Sales & Book Value Annual Sales$399.58 million Price / Sales6.16 Cash Flow$0.10 per share Price / Cash Flow334.65 Book Value$14.74 per share Price / Book2.18Miscellaneous Outstanding Shares76,448,000Free Float75,454,000Market Cap$2.46 billion OptionableOptionable Beta1.65 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 54)CEO & Director Comp: $1.55MMs. Rebecca Chambers (Age 46)Executive VP & CFO Comp: $901.49kDr. Phillip G. Febbo M.D. (Age 58)Chief Scientific & Medical Officer Comp: $657.74kMs. Annie McGuire (Age 43)Executive VP, General Counsel & Chief People Officer Comp: $791.72kDr. John Leite Ph.D. (Age 52)Chief Commercial Officer for CLIA Business Comp: $1.53MMr. Jonathan Wygant (Age 53)VP & Chief Accounting Officer Mr. Steven FrenchSenior VP & Chief Information OfficerMs. Karen PossematoSenior Vice President of Corporate Marketing, Communications & Commercial OperationsMr. Robert Brainin (Age 53)Executive VP & Chief Business Officer Ms. Corinne DananSenior Vice PresidentMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHBurning Rock BiotechNASDAQ:BNRPACS GroupNYSE:PACSOption Care HealthNASDAQ:OPCHSotera HealthNASDAQ:SHCView All CompetitorsInsiders & InstitutionsTruist Financial CorpSold 920 shares on 8/21/2024Ownership: 0.017%Point72 Asset Management L.P.Bought 566,634 shares on 8/19/2024Ownership: 0.741%Algert Global LLCSold 11,241 shares on 8/16/2024Ownership: 0.051%The Manufacturers Life Insurance Company Bought 2,135 shares on 8/15/2024Ownership: 0.056%Point72 Asia Singapore Pte. Ltd.Bought 2,685 shares on 8/15/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $27.51 on January 1st, 2024. Since then, VCYT shares have increased by 17.6% and is now trading at $32.35. View the best growth stocks for 2024 here. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.10. The business's quarterly revenue was up 26.7% compared to the same quarter last year. Does Veracyte have any subsidiaries? Veracyte subsidiaries include HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. Who are Veracyte's major shareholders? Top institutional shareholders of Veracyte include ARK Investment Management LLC (8.91%), Dimensional Fund Advisors LP (4.53%), Sumitomo Mitsui Trust Holdings Inc. (4.16%) and William Blair Investment Management LLC (1.62%). Insiders that own company stock include John Leite, Giulia C Kennedy, Bonnie H Anderson, Evan/ Fa Jones, Karin Eastham, John L Bishop and Jens Holstein. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). This page (NASDAQ:VCYT) was last updated on 8/26/2024 by MarketBeat.com Staff From Our Partners[Free Event] A 3-Step Method To Generate Cash Flow From Stocks You Already OwnCharles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThis technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening rig...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCYT Stock Alerts